FDA 483 - Loba Feinchemie GmbH - November 03, 2025
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
Loba biotech GmbH, a drug substance manufacturer in Fischamend, Austria, was cited with seven observations during an FDA inspection. The inspection revealed significant deficiencies across manufacturing processes, quality systems, facility maintenance, and personnel training, indicating a lack of adequate control and oversight. Key issues include inadequate batch record documentation, unresolved aberrant conditions, deficient validations, and poor SOPs and deviation management.
ID · e4d6786f-ee91-4c59-8f82-2dd5ba6f7ecd